Patients with chromophobe RCC are more likely to experience complete recovery of kidney function after radical nephrectomy, and this is associated with better survival. While uncommon, complete ...

For patients with stage T1a renal cell carcinoma (RCC), the use of thermal ablation has been increasing, while the use of radical nephrectomy has been declining.

Cardiac transplant status is not significantly associated with adverse in-hospital outcomes in patients with kidney cancer ...

Nephron-sparing management is one strategy to reduce risks, according to investigators. Older age is significantly associated with greater kidney function decline after radical nephrectomy in patients ...

Background Laparoscopic radical nephrectomy (LRN) is the actual gold-standard for the treatment of clinically localized renal cell carcinoma (RCC) (cT1–2 with no indications for nephron-sparing ...

USA: Researchers have found that preoperative multiparametric MRI (mpMRI) could help predict the risk of chronic kidney ...

In patients with clinical stage 1 (cT1) renal masses, many physicians opt for nephron-sparing surgery, such as partial nephrectomy (PN) versus radical nephrectomy (RN). Both procedures have been shown ...

Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi). This is an ASCO Meeting Abstract from the 2023 ASCO ...

Background. A 57-year-old woman presented to the emergency department at a community hospital with a 2-month history of fatigue and right-sided flank and abdominal pain. Noncontrast CT of the abdomen ...

A significant proportion of patients undergoing radical nephrectomy (RN) for clear-cell renal cell carcinoma (RCC) develop chronic kidney disease (CKD) within a few years following surgery. Chronic ...

1. Which doctor should I consult for undergoing nephrectomy? You should consult a surgeon such as an Urologist. 2. Why should I have a kidney removed? You might have your kidney removed if it is ...

Hematologic toxicities in cancer patients treated with the multityrosine kinase sorafenib: A meta-analysis of clinical trials. Background: Postoperative chronic kidney disease (PCKD), defined as a ...